Sex matters in children living with HIV: sex differences in virological, immunological and proteomic outcomes in early-treated pediatric HIV

For decades, scientists have known that the human body responds differently to HIV depending on whether a person is male or female. In adults, these differences are well documented: women often carry lower amounts of the virus in their blood during the early stages of infection, yet they sometimes face higher risks of illness and death later on. This complex picture arises from a mix of biology and social circumstances. Biologically, sex hormones and genes on the X chromosome can shape how the immune system fights the virus. Socially, factors like access to healthcare and education influence how well a person can stick to their treatment. While these patterns are clear in grown-ups, it has remained a mystery whether they apply to children. Children are not simply small adults; their bodies are still growing, their immune systems are maturing, and the way they process medicine can be entirely different. Understanding whether boys and girls with HIV follow different paths from the very start of their lives is crucial for designing treatments that work for everyone.

A recent study set out to solve this puzzle by looking closely at children who were born with HIV but started treatment almost immediately after diagnosis. Researchers gathered data from 159 children across South Africa, Mozambique, and Mali. These children, roughly half boys and half girls, began taking antiretroviral therapy within the first few months of life, a strategy known to give them the best chance at a healthy future. The team tracked them for several years, measuring how quickly the virus disappeared from their blood, how much of the virus remained hidden in their cells, how their immune systems held up, and how well they followed their medication schedules. They also analyzed blood samples to see if boys and girls produced different levels of specific immune proteins.

The results revealed a striking difference in how the two sexes responded to treatment. Even though the girls started with slightly higher levels of the virus in their blood, they cleared it from their system faster than the boys. The data showed that for every year the children stayed on treatment, the girls' viral loads dropped more steeply than the boys'. This suggests that the female body may have a biological advantage in suppressing the virus once treatment begins. The researchers also looked at the "reservoir," which is the hidden stash of virus that hides inside cells and makes HIV impossible to cure completely. While the evidence here was less definitive, the data pointed in the same direction: the girls appeared to see a faster decline in this hidden virus than the boys did.

Perhaps most surprisingly, this biological edge for girls existed despite a social hurdle. The study found that girls were actually more likely than boys to have missed doses of their medication or faced interruptions in their supply. In many other health scenarios, missing medication leads to worse outcomes. Yet, in this group of children, the girls still managed to control the virus better and showed a lower risk of their immune systems deteriorating over time. This points strongly to an intrinsic biological factor helping girls fight the virus more effectively, even when their treatment was not perfect.

To understand the mechanism behind this, the scientists examined 92 different immune proteins in the blood. They found that girls had higher levels of several proteins involved in recruiting immune cells and signaling inflammation, including one called MCP-2. While high levels of inflammation can sometimes be harmful, in the context of early HIV treatment, this heightened immune activity might be the very thing helping girls keep the virus in check. The study suggests that the female immune system may be more aggressive or responsive to the virus right from the start of life.

The researchers were careful to note that while the findings are compelling, they are not yet a final verdict. The study was relatively small, and some of the differences, particularly regarding the hidden virus reservoir, were not statistically certain enough to be called absolute proof. However, the consistency of the results across different measurements—viral load, immune health, and protein levels—makes a strong case that sex matters in pediatric HIV. The study concludes that doctors and researchers can no longer treat boys and girls with HIV as a single group. To improve care and perhaps one day find a cure, the unique biological paths of each sex must be understood and respected from the earliest days of life.